Investigator

Robert W Sobol

Professor & Associate Director for Basic Research · Brown University, Department of Pathology and Laboratory Medicine & Legorreta Cancer Center

RWSRobert W Sobol
Papers(1)
Replication-associate…
Collaborators(2)
Wynand P RoosMd Ibrahim
Institutions(2)
South Australia Patho…California Northstate…

Papers

Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis

Abstract Poly(ADP-ribose) polymerases 1 and 2 (PARP1/PARP2), and poly(ADP-ribose) glycohydrolase (PARG), modulate the level of poly(ADP-ribose) (PAR), a post-translational protein modification, in response to DNA damage or replication stress. Here, we find that replication-dependent and PARP1/PARP2-mediated PARylation recruits the base excision repair (BER)/single-strand break repair (SSBR) scaffold protein XRCC1 and the associated factors DNA polymerase β (POLB), aprataxin (APTX), and DNA ligase isoform 3 (LIG3). Further, these BER/SSBR proteins promote resistance to inhibitors of PARP1/PARP2 and PARG, as loss of these proteins sensitizes glioblastoma and ovarian cancer cells to each. In addition, depletion of these replication-associated BER/SSBR factors leads to enhanced PAR levels and PARG inhibitor-induced activation of the ATR/CHK1 S-phase checkpoint kinases. Both PARG inhibition and ATR inhibition lead to elevated ATM- and DNA-PK-dependent KAP1 phosphorylation. In turn, inhibition of either ATR or CHK1 enhances the cellular response to PARG inhibitors. Finally, inhibition of the ATR regulators PRMT1 or PRMT5 synergizes with PARG inhibition, implicating replication-associated BER/SSBR and PARylation in the activation of the PRMT1/PRMT5/ATR axis. This study highlights the role of BER/SSBR in protecting the cell during S-phase to suppress PARylation-induced checkpoint activation, which may suggest a potential intervention strategy for PARG inhibitor-resistant tumors.

108Works
1Papers
2Collaborators
Cell Line, TumorBrain NeoplasmsDrug Resistance, NeoplasmOvarian NeoplasmsTumor Suppressor Protein p53Neoplastic Syndromes, HereditaryApoptosis

Positions

2022–

Professor & Associate Director for Basic Research

Brown University · Department of Pathology and Laboratory Medicine & Legorreta Cancer Center

2014–

Point Clear Charities Professor of Oncologic Sciences & Chief, Molecular & Metabolic Oncology Program

University of South Alabama Mitchell Cancer Institute · Pharmacology

2012–

Associate Professor

University of Pittsburgh · Pharmacology & UPCI

2002–

Assistant Professor

University of Pittsburgh · Pharmacology & UPCI

Education

1991

PhD

Temple University Health System · Biochemistry

1987

M.A.

Temple University · Chemistry

1982

B.S.

Allegheny College · Chemistry

Country

US

Links & IDs
0000-0001-7385-3563Brown vivo

Scopus: 7006164297

Researcher Id: E-4125-2013